Cumberland Pharmaceuticals Inc.
CPIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.13 | -0.26 | -0.10 | -2.18 |
| FCF Yield | -2.38% | 22.04% | 19.47% | 8.60% |
| EV / EBITDA | 196.97 | 10.34 | 102.03 | -68.34 |
| Quality | ||||
| ROIC | -12.97% | -17.65% | -8.84% | -11.61% |
| Gross Margin | 82.61% | 84.66% | 78.29% | 75.51% |
| Cash Conversion Ratio | 0.09 | -0.97 | -1.50 | -1.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.40% | 3.20% | 3.91% | 1.52% |
| Free Cash Flow Growth | -114.04% | -11.58% | 6.54% | 81.39% |
| Safety | ||||
| Net Debt / EBITDA | 14.30 | 0.04 | 3.61 | 12.80 |
| Interest Coverage | -10.62 | -14.31 | -9.74 | -78.32 |
| Efficiency | ||||
| Inventory Turnover | 1.65 | 1.32 | 0.92 | 1.05 |
| Cash Conversion Cycle | -436.67 | -477.20 | 76.12 | 19.59 |